StockNews.AI

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

StockNews.AI • 2 hours

AML
High Materiality9/10

Information

REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-sta...

Original source

AI Summary

Exicure, Inc. (XCUR) will present promising data on burixafor, enhancing stem cell mobilization for multiple myeloma patients, at the ASTCT meeting on February 5. This could significantly impact treatment options, as over 89% of trial participants achieved key outcomes, indicating potential for future growth in Exicure's market position.

Sentiment Rationale

The positive clinical trial results and upcoming presentation at a major conference create optimism. Past instances of trial success in biotech stocks often lead to significant price increases.

Trading Thesis

XCUR is likely to see positive momentum leading up to and following the ASTCT meeting.

Market-Moving

  • Presentation at ASTCT could generate investor interest and drive stock price up.
  • Positive trial results enhance XCUR's competitive edge in hematologic treatments.
  • Further trials in AML and sickle cell disease could expand market potential.

Key Facts

  • Exicure will present a poster at the ASTCT meeting on February 5.
  • Positive topline data shows burixafor's effectiveness in stem cell mobilization.
  • 89.7% of trial patients met the primary endpoint with favorable safety.
  • Burixafor enhances stem cell movement for autologous transplantation procedures.
  • The company aims to target multiple hematologic diseases with burixafor.

Companies Mentioned

  • Exicure, Inc. (XCUR): Focus on advancing hematologic therapy through burixafor.

Corporate Developments

The announcement relates to advancements in biotechnology and treatment solutions, specifically in hematologic conditions. This fits the 'Corporate Developments' category due to the emphasis on ongoing trials and product enhancements.

Exicure to Present Burixafor Trial Data at 2026 Tandem Meetings

Date: January 21, 2026 | Source: GlobeNewsWire

Overview of the Presentation

Exicure, Inc. (Nasdaq: XCUR), a prominent clinical-stage biotechnology firm specializing in treatments for hematologic diseases, has announced a significant poster presentation at the upcoming 2026 Tandem Meetings. This event, organized by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), will take place from February 4-7, 2026, in Salt Lake City, UT.

Clinical Insights from the Phase 2 Trial

The poster will detail results from Exicure’s open-label, multicenter Phase 2 trial (NCT05561751), which focuses on the efficacy of burixafor in patients diagnosed with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). Recent topline data from this study demonstrates burixafor’s capability in mobilizing hematopoietic progenitor cells through the blockade of the CXCR4 receptor, crucial for retaining stem cells within the bone marrow.

Challenges and Solutions in Stem Cell Mobilization

As noted by Dr. Yosra Aljawai, the lead investigator from MD Anderson Cancer Center, effective stem cell mobilization poses significant challenges, especially for multiple myeloma patients. The current treatment landscape often includes agents like lenalidomide and daratumumab, limiting mobilization options. Dr. Aljawai stated, “In our Phase 2 study, burixafor in combination with propranolol and G-CSF provided reliable mobilization and a favorable safety profile. 89.7% of the patients successfully met the primary endpoint…”

This advancement presents a critical alternative for patients facing barriers to successful stem cell collection.

Presentation Details

  • Abstract Number: 29283
  • Title: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Patients with Multiple Myeloma
  • Presenter: Dr. Yosra Aljawai, Assistant Professor, MD Anderson Cancer Center
  • Session: Graft sources, mobilization, donor safety
  • Date and Time: February 5, 2026, at 6:30 PM

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) is dedicated to developing innovative therapies aimed at overcoming significant challenges in hematologic diseases. Its lead program, burixafor (GPC-100), acts as a selective small molecule antagonist of the CXCR4 receptor, supporting enhanced stem cell mobilization for AHCT.

Burixafor is currently under evaluation for its potential in treating multiple myeloma, sickle cell disease, and facilitating cell and gene therapy applications. Following its acquisition of GPCR Therapeutics, Inc. in January 2025, Exicure has solidified burixafor's role within its therapeutic pipeline.

Contact Information

For media inquiries, please contact:

Sarah Ellinwood, PhD
Kendall Investor Relations
sellinwood@kendallir.com

Related News